By inducing the lysis of malignant cells, oncolytic viruses release a broad spectrum of neoantigens that can prime a patient’s native immune system through a process called epitope spreading. This mechanism represents a significant shift from the current clinical standard of single-target Chimeric
The current pharmaceutical landscape is witnessing a profound transformation as the successful clinical implementation of personalized mRNA cancer vaccines begins to redefine the standard of care in oncology. This seismic shift is driven by a long-held vision: the ability to train a patient’s own
The oncology sector is shifting its primary focus from simply managing terminal disease to achieving functional cures that allow patients to live long, healthy lives. This transition marks a departure from the historical reliance on broad-spectrum treatments that often came with debilitating side
The approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant marks the first time a liquid biopsy has been authorized for continuous monitoring of cancer evolution. This regulatory milestone fundamentally alters the management of advanced breast cancer by allowing
While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer
The inherent inefficiencies of the autologous model are tied to a one-batch-per-patient approach that restricts throughput and maintains high market prices for oncology treatments. While Chimeric Antigen Receptor (CAR) T-cell therapies have redefined oncology by providing life-saving results for